Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function
August 17, 2022 08:35 ET
|
PalisadeBio
CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function
June 29, 2022 08:30 ET
|
PalisadeBio
Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of...
Palisade Bio to Present at the 2022 BIO International Convention
June 07, 2022 08:30 ET
|
PalisadeBio
CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 13, 2022 09:00 ET
|
PalisadeBio
Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal...
Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires
May 10, 2022 17:00 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications,...
Palisade Bio Announces $2.0 Million Registered Direct Offering
May 06, 2022 08:30 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and...
Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
May 05, 2022 08:30 ET
|
Palisade Bio, Inc.
NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase...
Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements
May 02, 2022 08:35 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event
April 29, 2022 08:05 ET
|
Palisade Bio, Inc.
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...